Mikenac- Amarin is in need of a larger footprint. At this point Amarin isn't engaging in M&A, Amarin is executing their business plan, get Vascepa a strong and wide cardiovascular label based on the landmark R-I trial results. In the course of business Amarin is in the process of kicking ass in court. Here are active cases:
1) Patent fight with left-over generics after TEVA settled for 2029. Case is active in Nevada.
2) Amarin v. ITC (Really FDA). Case is waiting for a decision from Federal Court of Appeals.
3) Prosecuting 2 Supplement "fish oil" company's for falsely advertising using R-I landmark results. Case is active although is heavily leaning toward settlements in to separate California District Courts, Southern & Central.
IMO none of the above cases are even close to being resolved unfavorably regarding Amarin business.
Amarin doesn't NEED J&J or PFE or any other stupid BP that should have had the brains to engage in M&A in 2012.
BB
News 
Market Data 
Discover 
